AI assistant
Sending…
UroGen Pharma Ltd. — Director's Dealing 2021
May 18, 2021
32312_dirs_2021-05-18_ed5ffb98-e457-4188-8769-d2d27d311402.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2021-05-17
Reporting Person: Henderson Molly (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-05-17 | Common Stock | P | 2500 | $15.85 | Acquired | 2500 | Direct |
More from UroGen Pharma Ltd.
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Proxy Solicitation & Information Statement
2026
Apr 30
Annual Report
2026
Mar 2
Regulatory Filings
2026
Mar 2
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 11
Director's Dealing
2026
Feb 4